ClinicalTrials.gg
Sign In
Not yet recruitingNCT07278648Updated Oct 27, 2026

High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department

An observational study in Acute Disease, sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Consorci Sanitari de l'Alt Penedès i Garraf · Observational

Updated Oct 27, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or hemorrhagic event related to the treatment.

02

Conditions studied

  • Acute Disease

Browse trials for

Keywords

  • Antithrombotic Treatment
  • Hemorragic Event
  • Anticoagulants
03

In context

Acute Disease

57 studies on the registry are indexed under Acute Disease; 12 are open to participants now.

This study's planned enrollment of 150 is below the median of 900 across 22 observational studies indexed under Acute Disease.

Browse Acute Disease studies →

Lead sponsor

Consorci Sanitari de l'Alt Penedès i Garraf is the lead sponsor of 41 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who has been discharged from an acute care unit with anticoagulant therapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients discharged from the Emergency Department (ED) and acute care units with an electronic prescription for at least one anticoagulant medication (new or ongoing), identified with the following codes:

B01AA - Vitamin K antagonists: warfarin and acenocoumarol

B01AB - Heparin group: low-molecular weight heparins such as enoxaparin, tinzaparin, bemiparin, …

B01AE - Direct thrombin inhibitors: dabigatran

B01AF - Direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban

Exclusion criteria

Exclusion Criteria:

  • Those who are not part of the CSAPG healthcare area.
  • Patients discharged from outpatient clinics, home hospitalization units, intermediate care, or residential facilities.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Anticoagulant therapy

    Patients who has been discharged from hospital with anticoagulant therapy

    Other: Antithrombotic therapy

Interventions

  • OtherAntithrombotic therapy

    Anticoagulant treatment prescribed at discharge from an acute care unit

06

What researchers measure

Primary outcomes

  1. Hemorragic event

    Proportion of patients who experience a hemorrhagic event within 90 days of hospital discharge

    Time frame: Day 90 from baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

Supporting information: Study protocol

Time frame: After publication of main results of the study.

Access criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Feb 2027; primary completion for Mar 2027, 0 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Feb 2026 → Feb 2027, primary completion Mar 2026 → Mar 2027 and completion Mar 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 12, 2025
StartEst.
Feb 5, 2027was Feb 2026
Primary completionEst.
Mar 1, 2027was Mar 2026
CompletionEst.
Mar 1, 2027was Mar 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 5, 2026→Feb 5, 2027
Oct 27, 2026
Primary completion
Mar 1, 2026→Mar 1, 2027
Oct 27, 2026
Study completion
Mar 1, 2026→Mar 1, 2027
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Start date Feb 5, 2026→Feb 5, 2027
    Primary completion Mar 1, 2026→Mar 1, 2027
    Study completion Mar 1, 2026→Mar 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07278648
Lead sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Feb 5, 2027 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Mar Saavedra
Contact
msaavedra@csapg.cat
0034938960025
Noemí Casaponsa
Contact
recerca@csapg.cat
0034938960025 ext. 43197

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acute Disease →

Other studies from this sponsor

Consorci Sanitari de l'Alt Penedès i Garraf

Start the discussion